Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/24/2008 First Published: 10/1/2001


1.		Phase III Randomized Study of Response-Based Chemotherapy With Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide With or Without Dexamethasone, Etoposide, Cytarabine, Cisplatin, and/or Radiotherapy in Children With Newly Diagnosed Intermediate-Risk Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				21 and under				NCI				COG-AHOD0031 NCT00025259, AHOD0031

Last Modified: 10/24/2008 First Published: 3/3/2006


2.		Phase III Study of Doxorubicin Hydrochloride, Vincristine, Prednisone, and Cyclophosphamide Followed by Response-Directed Radiotherapy in Children and Adolescents With Newly Diagnosed Low-Risk Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				21 and under				NCI				COG-AHOD0431 AHOD0431, NCT00302003

Last Modified: 5/23/2007


3.		Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Not specified				Other				MSKCC-95024 NCI-V95-0685, NCT00002663

Last Modified: 9/29/2008 First Published: 2/26/2008


4.		Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				BCM-H-19386 BCM-FAB, H 19386, NCT00625144


5.		Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				0 to 55				Other				8717 NCT00673114


6.		Therapy for Pediatric Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and under				Other				HOD99 NCT00145600

Last Modified: 1/4/2008 First Published: 6/22/2006


7.		Phase II Study of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin's or Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Under 70				NCI				UMN-2005LS048 UMN-0508M72589, UMN-MT2004-24, NCT00345865


8.		Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Natural history/Epidemiology, Treatment				Active				21 and under				Other				HOD05 NCT00352027

Last Modified: 5/22/2008 First Published: 5/4/2007


9.		Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				NCI				CINJ-3330 NCT00161187

Last Modified: 5/21/2008 First Published: 12/20/2007


10.		Phase II Study of Graft-Versus-Host Prophylaxis Comprising Sirolimus, Tacrolimus, and Anti-Thymocyte Globulin in Patients Undergoing Unrelated-Donor Hematopoietic Cell Transplantation For Hematological Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care, Treatment				Active				2 and over				NCI				CHNMC-06141 06141, NCT00589563

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute